Circadian rhythm as a therapeutic target

Find out how different pathways involved in the regulation of the circadian clock could be therapeutically targeted for a range of disorders in this review in the April issue.    

  • Wei Ruan
  • Xiaoyi Yuan
  • Holger K. Eltzschig
Review Article


    • Despite the rapid growth of the engineered cell therapy sector, there are challenges to the broader industrialization of cells as medicines, especially in the treatment of solid tumours. This Perspective provides an industry perspective on the progress achieved by engineered T cell therapies and discusses strategies to industrialize their potential.

      • Cedrik M. Britten
      • Aiman Shalabi
      • Axel Hoos
    • This Review discusses how recent advances in understanding the activation of the innate immune system are shedding light on the immunological mechanisms of action of adjuvants and highlights how systems-based approaches are beginning to revitalize adjuvant design and development.

      • Bali Pulendran
      • Prabhu S. Arunachalam
      • Derek T. O’Hagan
      Review Article
    • Antisense technology is now beginning to deliver on its promise to treat diseases by targeting RNA. Here, Crooke and colleagues describe the key technological advances that have enabled this progress and discuss recent clinical trials that illustrate the impact of these advances on the performance of antisense oligonucleotides in a wide range of therapeutic applications.

      • Stanley T. Crooke
      • Brenda F. Baker
      • Xue-hai Liang
      Review Article
    • Protein arginine methyltransferases (PRMTs) regulate numerous biological processes, including transcription, splicing and the DNA damage response. In this article, Barsyte-Lovejoy and colleagues discuss the development of PRMT inhibitors, predominantly for cancer, and describe the challenges and potential new indications in which PRMT inhibition could be therapeutically relevant.

      • Qin Wu
      • Matthieu Schapira
      • Dalia Barsyte-Lovejoy
      Review Article
    • Gasdermins (GSDMs) are a recently characterized protein family that mediate a programmed inflammatory cell death termed pyroptosis. Here, Lieberman and colleagues review current understanding of the expression, activation and regulation of GSDMs, highlighting their roles in cell death, cytokine secretion and inflammation. Emerging opportunities to develop GSDM-targeted drugs and the associated challenges are highlighted.

      • Xing Liu
      • Shiyu Xia
      • Judy Lieberman
      Review Article

Nature Careers